Published in J Virol on February 01, 2003
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol (2006) 1.62
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol (2005) 1.40
CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol (2003) 1.38
Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol (2006) 1.35
Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol (2007) 1.34
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology (2012) 1.31
Hepatitis C virus proteins. World J Gastroenterol (2007) 1.28
High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol (2004) 1.25
Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol J (2008) 1.21
Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol (2005) 1.21
Tetraspanins in viral infections: a fundamental role in viral biology? J Virol (2005) 1.16
Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding. J Virol (2007) 1.15
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol (2009) 1.07
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol (2014) 0.96
Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem (2012) 0.91
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry. J Biol Chem (2011) 0.91
Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. J Virol (2009) 0.89
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J Gen Virol (2010) 0.89
An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol (2013) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J Gen Virol (2011) 0.85
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity. J Biol Chem (2008) 0.84
Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. J Virol (2014) 0.83
Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry. J Biol Chem (2011) 0.82
A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81. PLoS One (2014) 0.82
Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain. J Biol Chem (2009) 0.80
Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function. J Virol (2012) 0.80
Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79
Interaction of the most membranotropic region of the HCV E2 envelope glycoprotein with membranes. Biophysical characterization. Biophys J (2008) 0.78
Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. PLoS One (2014) 0.77
Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection. PLoS One (2015) 0.76
Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. J Virol (2016) 0.76
Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display. Antimicrob Agents Chemother (2010) 0.75
Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells. Int J Mol Med (2015) 0.75
A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus. J Virol (2014) 0.75
Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo. Antimicrob Agents Chemother (2017) 0.75
An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that efficiently blocks virus entry. J Virol (2016) 0.75
Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy. Virol J (2011) 0.75
Epidemiology and Synergistic Hepatopathology of Malaria and Hepatitis C Virus Coinfection. Virology (Auckl) (2017) 0.75
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Binding of hepatitis C virus to CD81. Science (1998) 12.40
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis (2000) 6.54
The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell (2001) 5.65
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A (1992) 4.47
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol (1998) 4.01
Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol (2000) 3.26
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol (1994) 3.06
Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol (1993) 2.74
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med (2002) 2.68
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol (2001) 2.50
A model for the hepatitis C virus envelope glycoprotein E2. Proteins (2000) 2.17
Characterization of truncated forms of hepatitis C virus glycoproteins. J Gen Virol (1997) 2.06
CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J (2001) 1.90
Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol (2001) 1.90
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol (2000) 1.76
Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol (2000) 1.70
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol (2001) 1.67
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol (1995) 1.63
Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol (2000) 1.55
High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology (1998) 1.50
Therapy of hepatitis C. Semin Liver Dis (1995) 1.42
Full-length complementary DNA of hepatitis C virus genome from an infectious blood sample. Hepatology (1998) 1.26
Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis (1996) 1.19
Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology (1994) 1.09
Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology (2001) 1.08
Management of hepatitis C: a national survey of gastroenterologists and hepatologists. Hepatology (1997) 1.04
Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions. J Viral Hepat (2000) 0.94
Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol (2001) 0.94
Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization. Hepatology (2001) 0.90
Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol (1999) 0.89
In vitro models for hepatitis C. Virus Res (2002) 0.82
A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell (2011) 9.24
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99
The implications of alternative splicing in the ENCODE protein complement. Proc Natl Acad Sci U S A (2007) 3.93
Critical assessment of methods of protein structure prediction (CASP)--round x. Proteins (2013) 3.78
Critical assessment of methods of protein structure prediction-Round VII. Proteins (2007) 3.23
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12
The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. EMBO J (2002) 3.11
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
Evaluation of annotation strategies using an entire genome sequence. Bioinformatics (2003) 2.66
Critical assessment of methods of protein structure prediction (CASP)--round 6. Proteins (2005) 2.58
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Critical assessment of methods of protein structure prediction - Round VIII. Proteins (2009) 2.25
Assessment of predictions in the model quality assessment category. Proteins (2007) 2.25
Protein function annotation by homology-based inference. Genome Biol (2009) 2.20
Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun (2009) 2.08
Critical assessment of methods of protein structure prediction (CASP)--round IX. Proteins (2011) 2.08
Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol (2003) 2.03
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest (2004) 1.94
The PMDB Protein Model Database. Nucleic Acids Res (2006) 1.94
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther (2011) 1.92
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis (2012) 1.85
Ten simple rules for developing a short bioinformatics training course. PLoS Comput Biol (2011) 1.84
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther (2012) 1.76
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Assessment of the assessment: evaluation of the model quality estimates in CASP10. Proteins (2013) 1.60
PIGS: automatic prediction of antibody structures. Bioinformatics (2008) 1.59
Evaluating the usefulness of protein structure models for molecular replacement. Bioinformatics (2005) 1.58
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One (2012) 1.58
Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg (2005) 1.56
Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol (2010) 1.55
Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum Gene Ther (2002) 1.50
Evolution of bacterial and archaeal multicomponent monooxygenases. J Mol Evol (2003) 1.46
Evaluation of disorder predictions in CASP9. Proteins (2011) 1.46
Evaluation of CASP8 model quality predictions. Proteins (2009) 1.44
Evaluation of model quality predictions in CASP9. Proteins (2011) 1.43
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett (2008) 1.37
Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics (2009) 1.35
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine (2010) 1.29
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27
Evaluation of residue-residue contact predictions in CASP9. Proteins (2011) 1.26
Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog (2010) 1.25
Assessment of protein disorder region predictions in CASP10. Proteins (2013) 1.25
FunClust: a web server for the identification of structural motifs in a set of non-homologous protein structures. BMC Bioinformatics (2008) 1.23
Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry (2004) 1.21
Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther (2008) 1.21
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood (2009) 1.20
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica (2010) 1.17
Relationship between multiple sequence alignments and quality of protein comparative models. Proteins (2005) 1.16
Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem (2006) 1.15
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14